These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

740 related items for PubMed ID: 15452862

  • 1. Electron spin resonance spectroscopy reveals alpha-phenyl-N-tert-butylnitrone spin-traps free radicals in rat striatum and prevents haloperidol-induced vacuous chewing movements in the rat model of human tardive dyskinesia.
    Rogoza RM, Fairfax DF, Henry P, N-Marandi S, Khan RF, Gupta SK, Mishra RK.
    Synapse; 2004 Dec 01; 54(3):156-63. PubMed ID: 15452862
    [Abstract] [Full Text] [Related]

  • 2. Alpha-phenyl-N-tert-butylnitrone prevents oxidative stress in a haloperidol-induced animal model of tardive dyskinesia: investigating the behavioural and biochemical changes.
    Daya RP, Tan ML, Sookram CD, Skoblenick K, Mishra RK.
    Brain Res; 2011 Sep 15; 1412():28-36. PubMed ID: 21816389
    [Abstract] [Full Text] [Related]

  • 3. The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in rats.
    Turrone P, Remington G, Kapur S, Nobrega JN.
    Psychopharmacology (Berl); 2003 Jan 15; 165(2):166-71. PubMed ID: 12417967
    [Abstract] [Full Text] [Related]

  • 4. Possible anti-oxidant and neuroprotective mechanisms of zolpidem in attenuating typical anti-psychotic-induced orofacial dyskinesia: a biochemical and neurochemical study.
    Bishnoi M, Chopra K, Kulkarni SK.
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun 30; 31(5):1130-8. PubMed ID: 17513028
    [Abstract] [Full Text] [Related]

  • 5. Differential striatal levels of TNF-alpha, NFkappaB p65 subunit and dopamine with chronic typical and atypical neuroleptic treatment: role in orofacial dyskinesia.
    Bishnoi M, Chopra K, Kulkarni SK.
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug 01; 32(6):1473-8. PubMed ID: 18554768
    [Abstract] [Full Text] [Related]

  • 6. Increase in the effectiveness of somatodendritic 5-HT-1A receptors in a rat model of tardive dyskinesia.
    Samad N, Khan A, Perveen T, Haider S, Abdul Haleem M, Haleem DJ.
    Acta Neurobiol Exp (Wars); 2007 Aug 01; 67(4):389-97. PubMed ID: 18320717
    [Abstract] [Full Text] [Related]

  • 7. Behavioral responsitivity to dopamine receptor agonists after extensive striatal dopamine lesions during development.
    Neal-Beliveau BS, Joyce JN.
    Dev Psychobiol; 1998 May 01; 32(4):313-26. PubMed ID: 9589220
    [Abstract] [Full Text] [Related]

  • 8. Protective effect of Curcumin, the active principle of turmeric (Curcuma longa) in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes in rat brain.
    Bishnoi M, Chopra K, Kulkarni SK.
    Pharmacol Biochem Behav; 2008 Feb 01; 88(4):511-22. PubMed ID: 18022680
    [Abstract] [Full Text] [Related]

  • 9. Involvement of adenosinergic receptor system in an animal model of tardive dyskinesia and associated behavioural, biochemical and neurochemical changes.
    Bishnoi M, Chopra K, Kulkarni SK.
    Eur J Pharmacol; 2006 Dec 15; 552(1-3):55-66. PubMed ID: 17064683
    [Abstract] [Full Text] [Related]

  • 10. Valeriana officinalis does not alter the orofacial dyskinesia induced by haloperidol in rats: role of dopamine transporter.
    Fachinetto R, Villarinho JG, Wagner C, Pereira RP, Avila DS, Burger ME, Calixto JB, Rocha JB, Ferreira J.
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct 01; 31(7):1478-86. PubMed ID: 17669571
    [Abstract] [Full Text] [Related]

  • 11. The effect of chronic administration of sarizotan, 5-HT1A agonist/D3/D4 ligand, on haloperidol-induced repetitive jaw movements in rat model of tardive dyskinesia.
    Rosengarten H, Bartoszyk GD, Quartermain D, Lin Y.
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Mar 01; 30(2):273-9. PubMed ID: 16229932
    [Abstract] [Full Text] [Related]

  • 12. Protective effect of rutin, a polyphenolic flavonoid against haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes.
    Bishnoi M, Chopra K, Kulkarni SK.
    Fundam Clin Pharmacol; 2007 Oct 01; 21(5):521-9. PubMed ID: 17868205
    [Abstract] [Full Text] [Related]

  • 13. Neuroprotection by 2-h postischemia administration of two free radical scavengers, alpha-phenyl-n-tert-butyl-nitrone (PBN) and N-tert-butyl-(2-sulfophenyl)-nitrone (S-PBN), in rats subjected to focal embolic cerebral ischemia.
    Yang Y, Li Q, Shuaib A.
    Exp Neurol; 2000 May 01; 163(1):39-45. PubMed ID: 10785442
    [Abstract] [Full Text] [Related]

  • 14. Comparison of neuroprotective effects induced by alpha-phenyl-N-tert-butyl nitrone (PBN) and N-tert-butyl-alpha-(2 sulfophenyl) nitrone (S-PBN) in lithium-pilocarpine status epilepticus.
    Peterson SL, Purvis RS, Griffith JW.
    Neurotoxicology; 2005 Dec 01; 26(6):969-79. PubMed ID: 15890407
    [Abstract] [Full Text] [Related]

  • 15. The role of superoxide dismutase and alpha-tocopherol in the development of seizures and kindling induced by pentylenetetrazol - influence of the radical scavenger alpha-phenyl-N-tert-butyl nitrone.
    Rauca C, Wiswedel I, Zerbe R, Keilhoff G, Krug M.
    Brain Res; 2004 May 29; 1009(1-2):203-12. PubMed ID: 15120598
    [Abstract] [Full Text] [Related]

  • 16. Parallels between behavioral and neurochemical variability in the rat vacuous chewing movement model of tardive dyskinesia.
    Bachus SE, Yang E, McCloskey SS, Minton JN.
    Behav Brain Res; 2012 Jun 01; 231(2):323-36. PubMed ID: 22503783
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Glycine and D-cycloserine attenuate vacuous chewing movements in a rat model of tardive dyskinesia.
    Shoham S, Mazeh H, Javitt DC, Heresco-Levy U.
    Brain Res; 2004 Apr 09; 1004(1-2):142-7. PubMed ID: 15033429
    [Abstract] [Full Text] [Related]

  • 19. Neurochemical and behavioral effects of m-CPP in a rat model of tardive dyskinesia.
    Ikram H, Samad N, Haleem DJ.
    Pak J Pharm Sci; 2007 Jul 09; 20(3):188-95. PubMed ID: 17545102
    [Abstract] [Full Text] [Related]

  • 20. Progesterone attenuates neuroleptic-induced orofacial dyskinesia via the activity of its metabolite, allopregnanolone, a positive GABA(A) modulating neurosteroid.
    Bishnoi M, Chopra K, Kulkarni SK.
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb 15; 32(2):451-61. PubMed ID: 17988775
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.